Post by CeMM

16,906 followers

šŸ”¬ š—™š—æš—¼š—ŗ š—“š—æš—¼š˜‚š—»š—±š—Æš—æš—²š—®š—øš—¶š—»š—“ š—Æš—®š˜€š—¶š—° š—æš—²š˜€š—²š—®š—æš—°š—µ š˜š—¼ š—æš—²š—®š—¹-š˜„š—¼š—æš—¹š—± š˜š—µš—²š—æš—®š—½š—²š˜‚š˜š—¶š—° š—¶š—»š—»š—¼š˜ƒš—®š˜š—¶š—¼š—» Georg Winter, CeMM Adjunct PI and Scientific Director Life Sciences at AITHYRA Research Institute for Biomedical Artificial Intelligence, is a leading researcher in the field of glue degraders, small molecules that act as a "molecular glue," tagging disease-causing proteins for destruction by the cell's natural degradation mechanisms. What began as fundamental research at CeMM has evolved into Proxygen, a CeMM spin-off co-founded by Winter that is advancing this approach in collaboration with leading pharmaceutical companies to develop next-generation therapies. šŸ‘‰ Read the Austrian Science Fund FWF's Impact Story to learn more: https://bit.ly/4xwq61u šŸ“ø Bubu Dujmic / CeMM #BasicResearch #TPD #Biotech #LifeSciences

Post content